6 Result(s)

Article

Correction: Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design

I. Vaxman, S. K. Kumar, F. Buadi, M. Q. Lacy, D. Dingli, Y. Hwa, A. Fonder… in Leukemia (2024)

Article

Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience

I. Vaxman, S. K. Kumar, F. Buadi, M. Q. Lacy, D. Dingli, S. Hayman… in Blood Cancer Journal (2023)

Article

“Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience

Belantamab mafodotin is a highly selective targeted therapy for multiple myeloma. It targets the B cell maturation antigen (BCMA) on plasma cells and showed promising results in several randomized clinical tri...

I. Vaxman, J. Abeykoon, A. Dispenzieri, S. K. Kumar, F. Buadi… in Blood Cancer Journal (2021)

Article

Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design

I. Vaxman, S. K. Kumar, F. Buadi, M. Q. Lacy, D. Dingli, Y. Hwa, A. Fonder… in Leukemia (2021)

Article

Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma

We studied 190 patients with smoldering multiple myeloma (SMM) at our institution between 1973 and 2014. Evolving change in monoclonal protein level (eMP) was defined as ⩾10% increase in serum monoclonal prote...

P Ravi, S Kumar, J T Larsen, W Gonsalves, F Buadi, M Q Lacy, R Go… in Blood Cancer Journal (2016)